tiprankstipranks
Trending News
More News >
Eukedos S.p.A. (IT:EUK)
:EUK
Italy Market
Advertisement

Eukedos S.p.A. (EUK) AI Stock Analysis

Compare
0 Followers

Top Page

IT:EUK

Eukedos S.p.A.

(EUK)

Rating:46Neutral
Price Target:
€0.50
▼(-30.56% Downside)
Eukedos S.p.A. faces significant financial challenges, including high leverage and negative profitability, which are the most impactful factors on its stock score. Technical indicators suggest bearish momentum, further weighing on the stock's outlook. The valuation is also concerning due to the negative P/E ratio, indicating potential risks for investors.

Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)

Eukedos S.p.A. Business Overview & Revenue Model

Company DescriptionEukedos S.p.A. (EUK) is a leading company specializing in innovative technology solutions across various sectors, including healthcare, energy, and telecommunications. With a strong focus on research and development, EUK offers a diverse range of products and services designed to enhance efficiency and sustainability. Its core offerings include advanced data analytics platforms, IoT devices, and integrated software solutions that help businesses optimize operations and improve customer engagement.
How the Company Makes MoneyEukedos S.p.A. generates revenue through multiple streams, primarily from the sale of its technology products and services. Key revenue sources include licensing fees from its software solutions, subscription-based models for its data analytics platforms, and direct sales of IoT hardware. Additionally, EUK benefits from strategic partnerships with industry leaders, allowing for collaborative projects that enhance its product offerings and expand its market reach. The company also engages in consulting services, providing expert guidance to clients on technology implementation and optimization, which further contributes to its earnings.

Eukedos S.p.A. Financial Statement Overview

Summary
Eukedos S.p.A. demonstrates strong operational efficiency with high gross profit and EBITDA margins. However, the company faces challenges with profitability and high leverage, which could impact financial stability. Cash flow issues, particularly negative free cash flow, indicate potential liquidity concerns.
Income Statement
65
Positive
Eukedos S.p.A. shows a strong gross profit margin of 94.71% for 2024, indicating efficient cost management. However, the net profit margin is negative at -1.01%, reflecting challenges in converting revenue into profit. Revenue growth is modest at 1.96%, suggesting stable but slow expansion. The EBIT and EBITDA margins are healthy at 10.10% and 23.74%, respectively, showing operational efficiency.
Balance Sheet
50
Neutral
The company has a high debt-to-equity ratio of 3.32, indicating significant leverage, which could pose financial risks. Return on equity is negative at -1.76%, suggesting inefficiencies in generating returns for shareholders. The equity ratio is not provided, but the high leverage suggests limited equity relative to assets.
Cash Flow
40
Negative
Operating cash flow is positive, but free cash flow is negative, indicating potential liquidity issues. The free cash flow to net income ratio is -1.32, highlighting challenges in generating cash from operations. The operating cash flow to net income ratio of 0.34 suggests moderate cash generation efficiency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue51.69M49.45M47.04M45.18M46.99M
Gross Profit48.96M13.73M32.03M32.99M33.77M
EBITDA12.27M12.41M10.87M10.72M7.63M
Net Income-524.00K556.00K443.00K570.00K-1.92M
Balance Sheet
Total Assets179.34M149.10M153.38M150.08M146.26M
Cash, Cash Equivalents and Short-Term Investments3.91M2.33M3.62M7.39M2.64M
Total Debt99.02M105.83M111.45M108.95M102.89M
Total Liabilities149.50M119.19M123.99M121.26M118.02M
Stockholders Equity29.84M29.91M29.39M28.82M28.25M
Cash Flow
Free Cash Flow-13.14M3.59M1.03M5.31M1.27M
Operating Cash Flow9.94M10.08M5.18M5.61M6.68M
Investing Cash Flow-58.49M-8.92M-4.15M-306.00K-5.31M
Financing Cash Flow50.13M-2.45M-4.79M-562.00K-1.71M

Eukedos S.p.A. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
0.76
Negative
100DMA
0.77
Negative
200DMA
0.79
Negative
Market Momentum
MACD
-0.01
Positive
RSI
32.45
Neutral
STOCH
21.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.76, and below the 200-day MA of 0.79, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.45 is Neutral, neither overbought nor oversold. The STOCH value of 21.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:EUK.

Eukedos S.p.A. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.89B-0.33-41.61%2.23%23.26%-2.03%
46
Neutral
€16.37M24.13
6.68%-194.26%
€17.05M12.85
5.12%
€18.10M
€40.74M
€13.57M40.56
€43.81M7.82
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:EUK
Eukedos S.p.A.
0.72
-0.09
-11.11%
IT:ARBS
Arterra Bioscience SpA
2.52
0.57
29.23%
IT:COSMO
Farmacosmo S.P.A.
0.50
-0.20
-28.57%
IT:TALEA
Farmae SpA
4.80
-2.32
-32.58%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.56
0.51
48.57%
IT:SVS
Svas Biosana S.p.A.
8.14
0.67
8.97%

Eukedos S.p.A. Corporate Events

Eukedos S.p.A. Approves Financial and Remuneration Reports at Shareholders’ Meeting
Jun 30, 2025

Eukedos S.p.A. held its Ordinary Shareholders’ Meeting on June 30, 2025, where it approved the Financial Report for 2024, including the Sustainability Report, and decided to carry forward a loss of 15,491.49 euros. The company reported a consolidated production value of 51,676 million euros, with positive gross and net operating margins. Additionally, the 2025 Remuneration Report was approved, reflecting the company’s commitment to transparency and governance. These approvals demonstrate Eukedos S.p.A.’s focus on financial accountability and sustainable business practices.

Eukedos S.p.A. Releases Shareholders’ Meeting Minutes
Jun 9, 2025

Eukedos S.p.A. has made the minutes from its Ordinary Shareholders’ Meeting on May 9, 2025, accessible to the public. These documents are available at the company’s headquarters, through a storage mechanism online, and on the company’s website, enhancing transparency and accessibility for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 15, 2025